Ozempic face? Botox boom boosted by 'sagging face' trend, Swiss firm says
The aestetics company hope increased GLP-1 use will fuel demand for treatments addressing facial volume loss, sometimes dubbed "Ozempic face."
The trend of "Ozempic face" refers to the facial volume loss and sagging skin that some users of GLP-1 medications, such as Ozempic, have reported as a side effect. This has created a new opportunity for aesthetics companies to offer treatments that address these concerns. The Swiss firm's statement suggests that they are positioning themselves to capitalize on this trend, which could lead to increased demand for their products and services.
The potential boost to the aesthetics industry, particularly for companies offering facial rejuvenation treatments, is significant. As the use of GLP-1 medications continues to grow, driven by their effectiveness in treating conditions such as type 2 diabetes and obesity, the number of people experiencing facial volume loss and sagging skin is likely to increase. This could lead to a surge in demand for treatments such as fillers, facelifts, and other non-invasive procedures, which could have a positive impact on the revenue of companies operating in this space.
Investors in the aesthetics industry should watch for signs of increased demand for facial rejuvenation treatments, as well as the development of new products and services specifically designed to address the concerns associated with "Ozempic face". Companies that are well-positioned to capitalize on this trend, such as those with a strong portfolio of facial rejuvenation treatments, may see an increase in their stock price as the demand for these services grows. It will be important to monitor the sales and revenue of these companies, as well as any new product launches or partnerships, to gauge the impact of this trend on the industry.
Originally reported by cnbc.com. FundNews adds analysis for finance & markets readers.